Relevance of metabolic activation pathways: The example of clopidogrel and prasugrel

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 5, 2009, Pages 213-227

  Petersen, Karl Uwe ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b NONE   (Germany)

Author keywords

CAS 113665 84 2; CAS 150322 43 3; Clopidogrel; Cytochrome P450; Drug interactions; Omeprazole; Polymorphism; Prasugrel; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOPIDOGREL; CLOZAPINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DIAZEPAM; DRUG METABOLITE; EFAVIRENZ; KETOCONAZOLE; LANSOPRAZOLE; MACROLIDE; MORPHINE; NORTRIPTYLINE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PRASUGREL; PROPRANOLOL; RABEPRAZOLE; RIFAMPICIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; TAMOXIFEN; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CATALYSIS; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHENOTYPE; REVIEW; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS;

EID: 67149084496     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296388     Document Type: Review

References (93)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006;26:1895-1900. (Pubitemid 44305347)
2. Angiolillo DJ, Alfonso F. Clopidogrel-statin interaction: myth or reality? J AmColl Cardiol. 2007;50:296-298.
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516. (Pubitemid 46517957)
4. Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study (abstract). Circulation. 2008;118:S 815.
5. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-1660.
6. Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 2008;83:288-292.
7. Beitelshees AL, McLeod HL. Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol. 2006;26:1681-1683.
8. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther. 2001;70:391-394. (Pubitemid 33022480)
9. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 a;153:66.e9-16
10. nd, et al. Common polymorphisms of CYP 2C19 and CYP 2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007 b;5:2429-2436.
11. Calatzis A. Another view on prasugrel. Thromb Haemost 2009;101:12-13.
12. Cashman JR, Perotti BY, Berkman CE, Lin J. Pharmacokinetics and molecular detoxication. Environ Health Perspect. 1996;104 (Suppl 1):23-40.
13. Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy. Drug News Perspect. 2006;19:253-259. (Pubitemid 44186588)
14. Chen BL, Zhang W, Li Q, Li YL, He YJ, Fan L, et al. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP 2C19 genetic polymorphisms. Clin Exp Pharmacol Physiol. 2008;35:904-908. (Pubitemid 351953054)
15. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
16. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309-317.
17. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998;57:107-116. (Pubitemid 28063210)
18. Cytochrome P450 (CYP) Allele Nomenclature Committee. Allele nomenclature for Cytochrome P450 enzymes, 2008; available at http://www.cypalleles.ki.se (accessed on March 22, 2009)
19. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 2006;45:13-31. (Pubitemid 43145013)
20. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP 2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005;315:1085-1090. (Pubitemid 41635394)
21. 12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood. 2003;101:3908-3914.
22. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008;118:S 815.
23. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier- Perey M, et al. Nonresponse to clozapine and ultrarapid CYP 1A2 activity: clinical data and analysis of CYP 1A2 gene. J Clin Psychopharmacol. 2004;24:214-219. (Pubitemid 38380846)
24. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. Q J Med. 2000;93:391-423. (Pubitemid 30459919)
25. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549. (Pubitemid 36159890)
26. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007 a;35:1096-1104.
27. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007b;81:735-741.
28. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28:1483-1494.
29. FDA. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix), 2009; available at http://www.fda.gov/cder/drug/ early-comm/clopidogrel-bisulfate.htm (accessed on March 22, 2009)
30. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine; available at http://medicine.iupui.edu/ flockhart/table.htm (accessed on February 19, 2009)
31. Fontana P, Hulot JS, Moerloose P, Gaussem P. Influence of CYP 2C19 and CYP 3A4 gene polymorphism on clopidogrel responsiveness in healthy subjects. J Thromb Haemost. 2007;5:2153-2155. (Pubitemid 47450038)
32. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res. 2008;121:463-468. (Pubitemid 351174278)
33. Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. AmJ Cardiol. 2008;101:1088-1093.
34. Friesen MH. Issues that limit study conclusions. CMAJ 2009; available at http://www.cmaj.ca/cgi/eletters/cmaj. 082001v1#53931 (accessed on March 22, 2009)
35. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007;45:1230-1237. (Pubitemid 47580326)
36. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al. CYP 2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008;9:1251-1259.
37. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508-2509. (Pubitemid 44575451)
38. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J AmColl Cardiol. 2008;51:256-260.
39. 12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17:1057-1064.
40. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB J 1992;6:745-748.
41. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolismand toxicity. AAPS J 8:2006;E101-E111.
42. Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008;23:412-420.
43. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
44. Huang CW, Lai ML, Lin MS, Lee HL, Huang JD. Dose-response relationships of propranolol in Chinese subjects with different CYP 2D6 genotypes. J Chin Med Assoc. 2003;66:57-62. (Pubitemid 37265501)
45. Ieiri I, Kimura M, Irie S, Urae A, Otsubo K, Ishizaki T. Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP 2C19 genotypic status. Pharmacogenet Genomics. 2005;15:851-859. (Pubitemid 41666767)
46. Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 2006;21:173-185.
47. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Phil Trans R Soc B. 2005;360:1563-1570.
48. Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y, et al. CYP 2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther. 2005;78:647-655. (Pubitemid 41773640)
49. Ismail R, Teh LK. The relevance of CYP 2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin PharmTher. 2006;31:99-109.
50. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173 (Pubitemid 43752387)
51. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. (version subject to revision). A populationbased study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; Epub ahead of print, available at http://www.cmaj.ca/cgi/rapidpdf/cmaj.082001v1 (accessed on March 22, 2009)
52. Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol. 2008a;64:589-597.
53. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP 2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008b;84:236-242.
54. Krämer SD, Testa B. The biochemistry of drug metabolism - An introduction. Part 6. Inter-individual factors affecting drug metabolism. Chem Biodivers. 2008;5:2465-2578.
55. Lang T, Klein K, Richter T, Zibat A, Kerb R, EichelbaumM, et al. Multiple novel nonsynonymous CYP 2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles . J Pharmacol Exp Ther. 2004;311:34-41. (Pubitemid 39287781)
56. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32-37. (Pubitemid 36070929)
57. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-171. (Pubitemid 38114134)
58. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol. 2006;1:5-20.
59. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. (Pubitemid 38955611)
60. Ma MK, Woo MH, Mcleod HL. Genetic basis of drug metabolism. AmJ Health Syst Pharm. 2002;59:2061-2069. (Pubitemid 35257727)
61. Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G, et al. Coexisting polymorphisms of P2Y 12 and CYP 2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J. 2008;72:1165-1169. (Pubitemid 351957086)
62. Medsafe. Data Sheet Clopidogrel hydrogen sulfate. available at http://www.medsafe.govt.nz/Profs/Datasheet/p/Plavixtab.htm (accessed on March 14, 2009)
63. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362 (see also supplementary material)
64. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON- TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-731.
65. Mosca L, Arnett DK, Dracup K, Hansen BC, Labarthe DR, Marks JS, et al. American Heart Association. Task Force on Strategic Research Direction. Population/Outcomes/Epidemiology/Social Science Subgroup. Circulation. 2002;106:e167-172.
66. Mullangi R, Srinivas NR. Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Biomed Chromatogr. 2009;23:26-41.
67. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP 1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP 1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994;3:413-421. (Pubitemid 24221451)
68. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics . 1996;6:1-42. (Pubitemid 26096749)
69. Petersen KU. From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions. Arzneimittelforschung. 2002;52:423-429.
70. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286:2270-2279. (Pubitemid 33063150)
71. Rehmel JLF, Eckstein JA, Farid NA, Heim JB, Kasper S, Kurihara A, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metabol Dispos. 2006;34:600-607.
72. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab. 2002;3:289-309. (Pubitemid 34625041)
73. Rosemary J, Adithan C. The pharmacogenetics of CYP 2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol. 2007;2:93-109. (Pubitemid 46729082)
74. Savi, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896. (Pubitemid 30946954)
75. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313-317. (Pubitemid 24251300)
76. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:148.e1-5
77. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
78. Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995;5:335-346. (Pubitemid 26011440)
79. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-484.
80. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997;7:361-367. (Pubitemid 27427545)
81. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545-1551. (Pubitemid 46965386)
82. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006;74:1715-1722. (Pubitemid 43893560)
83. Terpening C. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. J AmBoard FamMed. 2009;22:51-56.
84. Testa B, Krämer SD. The biochemistry of drug metabolism - An introduction. Part 1. Principles and overview. Chem Biodivers. 2006;3:1053-1101.
85. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective PCI with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-1934. (Pubitemid 351636443)
86. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
87. Wang H, Tompkins LM. CYP 2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9:598-610.
88. Wehling, M. Translational Medicine: What is it and what could it be? Arzneimittelforschung. 2009;59:3-7.
89. Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2 . Drug Metab Dispos. 2008;36:1227-1232. (Pubitemid 351929304)
90. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004;109:3064-3067.
91. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al. Role of polymorphic human CYP 2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003;3:53-61. (Pubitemid 36432466)
92. Yoneda K, Iwamura R, Kishi H, Mizukami Y, Mogami K, Kobayashi S. Identification of the active metabolite of ticlopidine from rat in vitro metabolites. Br J Pharmacol. 2004;142:551-557. (Pubitemid 38869869)
93. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP 3A5 and MDR1 gene polymorphisms. AmJ Transplant. 2003;3:477-483. (Pubitemid 36560101)